Black Rock Inc. Cardiff Oncology, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 2,628,407 shares of CRDF stock, worth $5.31 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,628,407
Previous 677,458
287.98%
Holding current value
$5.31 Million
Previous $3.62 Million
61.32%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CRDF
# of Institutions
126Shares Held
25.8MCall Options Held
1.01MPut Options Held
293K-
Vanguard Group Inc Valley Forge, PA3.73MShares$7.53 Million0.0% of portfolio
-
Blair William & CO Chicago, IL2.52MShares$5.1 Million0.02% of portfolio
-
Laurion Capital Management LP New York, NY1.8MShares$3.63 Million0.11% of portfolio
-
Geode Capital Management, LLC Boston, MA1.5MShares$3.03 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.42MShares$2.87 Million0.01% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $87.5M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...